Strategic Investment Advisors MI Increases Stock Position in United Therapeutics Corporation $UTHR

Strategic Investment Advisors MI grew its holdings in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 20.5% during the first quarter, HoldingsChannel.com reports. The institutional investor owned 9,752 shares of the biotechnology company’s stock after buying an additional 1,662 shares during the period. Strategic Investment Advisors MI’s holdings in United Therapeutics were worth $5,782,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Torren Management LLC bought a new position in shares of United Therapeutics in the 4th quarter worth about $26,000. Activest Wealth Management boosted its stake in United Therapeutics by 1,400.0% during the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 56 shares in the last quarter. Entrust Financial LLC bought a new stake in United Therapeutics during the fourth quarter worth about $31,000. International Assets Investment Management LLC grew its holdings in United Therapeutics by 426.7% in the first quarter. International Assets Investment Management LLC now owns 79 shares of the biotechnology company’s stock worth $45,000 after purchasing an additional 64 shares during the period. Finally, Wilmington Savings Fund Society FSB grew its holdings in United Therapeutics by 125.6% in the third quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock worth $37,000 after purchasing an additional 49 shares during the period. 94.08% of the stock is owned by hedge funds and other institutional investors.

More United Therapeutics News

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Promising ralinepag trial results: The Lancet published full results from United Therapeutics’ ADVANCE OUTCOMES study. Investigational pulmonary arterial hypertension treatment ralinepag reduced the risk of clinical worsening by 55% versus placebo, improving the company’s potential pipeline outlook. Ralinepag is not yet approved by the FDA, so regulatory and commercialization risks remain. United Therapeutics Announces ADVANCE OUTCOMES Study of Ralinepag Published in The Lancet
• Positive Sentiment: Analyst support remains strong: Eleven analysts rate UTHR a Buy and two rate it a Hold, producing a consensus “Moderate Buy” rating. The average price target is $648.33, with JPMorgan recently raising its target to $687 and HC Wainwright increasing its target to $660. United Therapeutics Given Average Rating of Moderate Buy by Brokerages
• Neutral Sentiment: Institutional ownership is high: Hedge funds and other institutional investors own approximately 94.1% of UTHR’s shares. Several institutions increased their positions during the second quarter, signaling continued professional-investor interest, although this does not guarantee further gains. United Therapeutics Insider Trading Report
• Negative Sentiment: CEO stock sale may pressure sentiment: CEO Martine Rothblatt sold 9,500 shares for roughly $5.04 million, reducing her direct stake by 2.84%. She still owns a substantial position, so the transaction may reflect liquidity or diversification rather than a negative view of the business, but insider selling can weigh on investor confidence. Insider Selling United Therapeutics CEO Sells Stock
• Negative Sentiment: Recent operating results were below expectations: United Therapeutics previously reported quarterly earnings and revenue below consensus, with revenue declining 1.6% year over year. That performance remains a concern despite the company’s strong profitability and promising pipeline.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the stock. Royal Bank Of Canada lifted their target price on shares of United Therapeutics from $701.00 to $704.00 and gave the company an “outperform” rating in a report on Tuesday, July 7th. Bank of America cut their price target on United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a research note on Friday, July 10th. Morgan Stanley set a $516.00 price objective on United Therapeutics in a research report on Thursday, May 7th. JPMorgan Chase & Co. lifted their price objective on United Therapeutics from $685.00 to $687.00 and gave the company an “overweight” rating in a research note on Thursday, July 23rd. Finally, Raymond James Financial began coverage on United Therapeutics in a report on Friday, April 10th. They issued an “outperform” rating and a $700.00 target price on the stock. Eleven analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $648.33.

United Therapeutics Stock Performance

NASDAQ UTHR opened at $524.70 on Thursday. United Therapeutics Corporation has a one year low of $272.12 and a one year high of $609.35. The stock has a 50-day moving average of $545.45 and a 200 day moving average of $532.24. The company has a market capitalization of $22.27 billion, a price-to-earnings ratio of 19.37, a PEG ratio of 1.75 and a beta of 0.58.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing the consensus estimate of $7.00 by ($1.18). The company had revenue of $781.50 million for the quarter, compared to the consensus estimate of $797.40 million. United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. United Therapeutics’s revenue was down 1.6% on a year-over-year basis. During the same quarter in the prior year, the company posted $6.63 EPS. On average, equities analysts predict that United Therapeutics Corporation will post 26.65 earnings per share for the current fiscal year.

Insider Buying and Selling at United Therapeutics

In related news, CFO James Edgemond sold 10,000 shares of the stock in a transaction that occurred on Thursday, May 7th. The shares were sold at an average price of $578.58, for a total transaction of $5,785,800.00. Following the transaction, the chief financial officer owned 18,876 shares in the company, valued at $10,921,276.08. This represents a 34.63% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold 502,833 shares of company stock worth $279,835,157 over the last three months. 8.60% of the stock is owned by insiders.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.